Market Overview

UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

Share:
Related TEVA
Will Allergan Buy Gilead? Don't Count On 'The Mother Of All Blockbusters'
Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma
Amgen, Biogen Pitted In M&A Scenario; Adamas, Acadia Draw Interest (Investor's Business Daily)

On Friday, JP Morgan upgraded shares of Teva Pharmaceuticals (NYSE: TEVA) from Underweight to Neutral and raised the profit target to $49.

Analyst Chris Schott is encouraged by “favorable initial Copaxone 3x weekly trends and the potential for additional cost cutting activity,” but remains “less enthusiastic around Teva's organic growth prospects and its P&L reliance on Copaxone.”

Schott expects Teva management's “willingness to consider larger business development opportunities will be well received.”

Shares of Teva are up 21 percent year-to-date and up 1.8 percent to $48.82 during Friday's session.

Latest Ratings for TEVA

DateFirmActionFromTo
Sep 2016OppenheimerUpgradesPerformOutperform
Aug 2016Leerink SwannMaintainsOutperform
Aug 2016BTIG ResearchMaintainsBuy

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Chris Schott JP MorganAnalyst Color Analyst Ratings

 

Related Articles (TEVA)

View Comments and Join the Discussion!